Pfizer Inc and partner BioNTech SE said on Wednesday they signed a $3.2 billion deal with the U.S. government for 105 million doses of their COVID-19 vaccine, which could be delivered as soon as later this summer.
said on Wednesday they signed a $3.2 billion deal with the U.S. government for 105 million doses of their COVID-19 vaccine, which could be delivered as soon as later this summer.
Drugmakers have been developing vaccines to target the Omicron variant that became dominant last winter.The average price per dose in the new deal is over $30, a more than 50% increase from the $19.50 per dose the U.S. government paid in its initial contract with Pfizer. "We look forward to taking delivery of these new variant-specific vaccines and working with state and local health departments, pharmacies, healthcare providers, federally qualified health centers, and other partners to make them available in communities around the country this fall," U.S. Health and Human Services official Dawn O’Connell said in a statement.
The new contract should boost 2022 vaccine sales for Pfizer and BioNTech, which share profits from the shots. Pfizer has forecast COVID-19 vaccine sales of $32 billion this year. Analysts, on average, have forecast 2022 sales of around $33.6 billion for the shots.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Montgomery approves $3.4M bid for Garrett Coliseum renovationThe city of Montgomery has signed off on a $3.4 million construction bid to renovate about 20,000 square feet of Garrett Coliseum.
Read more »
Pfizer Says Updated Vaccines Boost Protection Against OmicronThe announcement comes just as the FDA is deciding whether or not to recommend vaccine recipe changes.
Read more »
BioNTech, Pfizer to start testing next-generation vaccine for coronavirusesThe two partners, makers of the Western world's most widely used Covid-19 shot, are currently discussing with regulators enhanced versions of their established shot to better protect against the Omicron variant and its sublineages.
Read more »
Pfizer Says Updated Vaccines Boost Protection Against OmicronPfizer and BioNTech announced that their two Omicron-targeted vaccines are safe and effective against the coronavirus, including the latest Omicron subvariants. This new formulation could be used as a fourth shot — or a second booster — to better protect against another coronavirus surge expected this fall and winter.
Read more »